EGFR and neoplasm: Whilst a handful of protein targets have been explored for CAR T cell therapy for GBM,9, 10, 11 a truncation mutation of the epidermal growth factor receptor (EGFR), EGFRvIII, has been of great clinical focus because of its tumor‐restricted expression.12